Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tumours

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

- PMLiVE

Ipsen strengthens neurology efforts with Syntaxin purchase

French pharma firm also agrees research deal with Harvard

- PMLiVE

Analysts question value of rumoured $20bn Roche bid for Alexion

Shares in orphan drug specialist slide back after earlier surge

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

Deal Watch table for June 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

- PMLiVE

FDA grants orphan status to Activartis’ brain cancer immunotherapy

Regulator says AV0113 has potential in rare cancer malignant glioma

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

- PMLiVE

Merck Serono pushes into immunotherapies for cancer

Pharma company sets up dedicated R&D unit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links